Investment
Features
FeesSafety
Academy
More
Pluang+

Hims & Hers outperforms 10x Genomics in profitability, revenue, and analyst outlook.

Analyst Insights
23 Mar 2026
Defense World
View Source
Bullish
pluang ai news

Hims & Hers Health shows stronger financial performance than 10x Genomics, with higher revenue, net income, and profitability metrics. Despite 10x Genomics being more affordable by price-to-earnings ratio, Hims & Hers has a higher analyst consensus rating and a larger potential upside of 42.25%. Both companies operate in the medical sector but differ in business focus, with Hims & Hers in telehealth and 10x Genomics in life science technology. Investors may favor Hims & Hers due to its stronger fundamentals and growth prospects.

More News (HIMS)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App